|Systematic (IUPAC) name|
|Molar mass||267.322 g/mol[[Script error: No such module "String".]]|
Dihydrexidine (LS-186,899) is a selective full agonist at the dopamine D1 and D5 receptors. It has approximately 10-fold selectivity for D1 and D5 over the D2 receptor. Dihydrexidine was investigated for the treatment of Parkinson's disease and schizophrenia but in an early clinical trial the drug was given intravenously and led to profound hypotension so development was halted. This drug continues to be studied, however, and is now in clinical trials to assess its efficacy in improving the cognitive and working memory deficits in schizophrenia.
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|40px||This antihypertensive-related article is a stub. You can help ssf by expanding it.|